Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
Cancer Immunol Immunother. 2022 Sep;71(9):2183-2184.
doi: 10.1007/s00262-022-03218-0.
1 Department of Internal Medicine, Division of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, 5323 Harry Hines Blvd., Mail Code 8852, Dallas, TX, 75390-8852, USA.
2 Harold C. Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, Dallas, TX, 75390, USA.
3 School of Medicine, University of Texas, Southwestern Medical Center, Dallas, TX, 75390, USA.
4 Department of Population and Data Sciences, University of Texas, Southwestern Medical Center, Dallas, TX, 75390, USA.
5 Stanford University, Palo Alto, CA, USA.
6 Department of Internal Medicine, Division of Endocrinology, University of Texas, Southwestern Medical Center, Dallas, TX, 75390, USA.
7 Academic Information Systems, University of Texas, Southwestern Medical Center, Dallas, TX, 75390, USA.
8 Department of Internal Medicine, Division of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, 5323 Harry Hines Blvd., Mail Code 8852, Dallas, TX, 75390-8852, USA. david.gerber@utsouthwestern.edu.
9 Harold C. Simmons Comprehensive Cancer Center, University of Texas, Southwestern Medical Center, Dallas, TX, 75390, USA. david.gerber@utsouthwestern.edu.
10 Department of Population and Data Sciences, University of Texas, Southwestern Medical Center, Dallas, TX, 75390, USA. david.gerber@utsouthwestern.edu.